Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
74.05
+0.54
+0.73%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
👀 Ones to watch: The MOST undervalued shares to buy right now
See Undervalued Shares
Blackrock Health Sciences Opportunities Portfolio Institutional Shares (SHSSX)
Add to/Remove from a Portfolio
Add to Watchlist
25/11 - Delayed Data. Currency in USD
- Morningstar Rating:
- Total Assets: 4.1B
BlackRock Health Sciences Opps Instl
74.05
+0.54
+0.73%
- General
- Chart
- News & Analysis
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Holdings
SHSSX Overview
On this page you'll find an in-depth profile of Blackrock Health Sciences Opportunities Portfolio Institutional Shares. Learn about the key management, total assets, investment strategy and contact information of SHSSX among other information.
Investment Strategy
The investment seeks to provide long-term growth of capital. The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.
Contact Information
Address
12 Throgmorton Avenue
London,RI EC2N 2DL
United Kingdom
London,RI EC2N 2DL
United Kingdom
Phone
020 7743 3000
Top Executives
| Name | Title | Since | Until |
|---|---|---|---|
| Xiang Liu | Director | 2020 | Now |
| Biography | Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000. | ||
| Erin Xie | Managing Director | 2003 | Now |
| Biography | Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999. | ||
| Jeff Lee | - | 2020 | 2023 |
| Biography | Jeffrey Lee, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the healthcare providers and services sector. Prior to joining BlackRock in 2011, Mr. Lee was a member of the healthcare investment team at Duquesne Capital Management where he covered provider and service companies. From 2006 to 2008, Mr. Lee was an healthcare private equity associate at Altaris Capital Partners where he sourced and analyzed equity transactions for public and private healthcare companies. Prior to 2006, Mr. Lee was an analyst at Citigroup within the healthcare finance and investment banking group where he valued and helped structured financing for managed care providers, hospital companies and other large healthcare systems. Mr. Lee earned a BA degree in economics, cum laude, from Princeton University in 2004. | ||
| Thomas P. Callan | Managing Director | 2005 | 2017 |
| Biography | Thomas P. Callan, CFA, Managing Director and senior portfolio manager, is head of BlackRock's Global Opportunities equity team. He oversees the team's investment process, leads the team's Investment Strategy Group, and provides portfolio and risk management oversight for all of the team's products. In addition, Mr. Callan is a member of BlackRock's Leadership Committee. Mr. Callan's service with the firm dates back to 1988, including his years with PNC Asset Management Group, which was integrated with BlackRock in 1998. He started as a health care analyst for PNC's mutual fund group and later served as an international equity analyst. Mr. Callan began his investment career at PNC Bank as a personal trust portfolio manager in 1988. Mr. Callan earned a BA degree in economics, with honors, from Boston College in 1981. | ||
| Ajay Mehra | Managing Director | 2003 | 2005 |
| Biography | Prior to founding Foresight Global Investors, Ajay was a Managing Director and Head of Equities at Salient Partners where he managed their global equity strategy in both SMA and Mutual Fund (SGEIX) format. Prior to Salient, Dr. Mehra served as Managing Director and Head of Manager and Fund Research at UBS. In this role, he was responsible for overseeing the manager search and ongoing due diligence activities for the group. Dr. Mehra was also a Partner and Portfolio Manager at private equity firm Columbus Nova, where he co-managed a global macro fund, did principal investments and managed a long biased global equity fund. Dr. Mehra has also held the positions of Managing Director and Head of Equity Research for State Street Research, where he was the lead portfolio manager for a Health Sciences fund (selected as the Lipper Best Health Sciences Fund 2003 and 2004) and a Large-Cap fund. Prior to joining State Street Research, he was a Senior Vice President and Portfolio Manager for Columbia Management Group. Ajay began his investment career at Morgan Stanley where he was the firm's Consumer Products analyst. Prior to that, he was Assistant Professor of Strategic Management at West Virginia University's College of Business and Economics. Dr. Mehra holds a B.S. and M.B.A. from Panjab University in Chandigarth, India. He also earned a Ph.D. from the University of Massachusetts, where his doctoral dissertation was selected as a finalist for the Best Dissertation award by the Academy of Management and was subsequently published as a book | ||
| Management Team | - | 2003 | 2003 |
| Biography | Team Managed | ||
| John R. Borzilleri | Portfolio Manager | 1999 | 2003 |
| Biography | John R. Borzilleri, MD is a general partner and portfolio manager for the GRT Health Care Fund. Dr. Borzilleri has thirteen years of experience in investment management and research. From inception in late 1999 until his departure in June 2003, Dr. Borzilleri was the portfolio manager of the State Street Research and Management Health Sciences Fund. For the three years ending June 2003, the Health Sciences Fund reported annualized returns of +12.89, representing top decile Lipper performance in the health care category. From 1997 until his departure, Dr. Borzilleri was also a senior health care analyst at State Street Research, with broad coverage of the pharmaceutical, biotechnology and medical service sectors. For his last 2 years at State Street Research, Dr. Borzilleri was the health care sector head, with responsibility for managing a team of 3 other analysts. From October 1995 to June 1997, Dr. Borzilleri was the senior pharmaceutical analyst at San Francisco-based Montgomery Securities, with analytic responsibility for large, mid and small capitalization drug companies. From October 1993 to October 1995, Dr. Borzilleri was the senior pharmaceutical and biotechnology analyst at Dean Witter in New York. From August 1991 to October 1993, Dr. Borzilleri was a junior pharmaceutical and biotechnology analyst at Sanford Bernstein. Dr. Borzilleri holds a BS degree in Biology from Brown University (’81), an MD from New York University (’85) and an MBA from Columbia University (’91). Between medical and business school, Dr. Borzilleri spent 5 years in residency training and the practice of medicine. | ||
Write your thoughts about Blackrock Health Sciences Opportunities Portfolio Institutional Shares
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review